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reamble
his document has been developed as a Clinical Expert
onsensus Document (CECD), by the American College of
ardiology Foundation (ACCF) and the American Heart
ssociation (AHA) in collaboration with the Society of Ath-
rosclerosis Imaging and Prevention (SAIP) and Society of
ardiovascular Computed Tomography (SCCT). It is in-
ended to provide a perspective on the current state of the
ole of coronary artery calcium (CAC) scoring by fast
omputed tomography in clinical practice. Clinical Expert
onsensus Documents are intended to inform practitioners,
ayers, and other interested parties of the opinion of the
CCF and AHA concerning evolving areas of clinical
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o the practice community. Topics chosen for coverage by
xpert consensus documents are so designed because the
vidence base, the experience with technology, and/or the
linical practice are not considered sufficiently well devel-
ped to be evaluated by the formal American College of
ardiology/American Heart Association (ACC/AHA)
ractice Guidelines process. Often the topic is the subject of
onsiderable ongoing investigation. Thus, the reader should
iew the CECD as the best attempt of the ACC and AHA
o inform and guide clinical practice in areas where rigorous
vidence may not yet be available or the evidence to date is
ot widely accepted. When feasible, CECDs include indi-
ations or contraindications. Some topics covered by
ECDs will be addressed subsequently by the ACC/AHA
ractice Guidelines Committee.
The Task Force on Clinical Expert Consensus Documents
akes every effort to avoid any actual or potential conflicts of
nterest that might arise as a result of an outside relationship or
ersonal interest of a member of the writing panel. Specifically,
ll members of the writing panel are asked to provide disclosure
tatements of all such relationships that might be perceived as
eal or potential conflicts of interest to inform the writing
ffort. These statements are reviewed by the parent task force,
eported orally to all members of the writing panel at the first
eeting, and updated as changes occur. The relationships with
ndustry information for writing committee members and peer
eviewers are published in the appendices of the document.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on Clinical Expert
Consensus Documents
ntroduction
he Writing Committee consisted of acknowledged experts in
he field of coronary artery disease. In addition to members of
CCF and AHA, the Writing Committee included represen-
atives from the SAIP and SCCT. Representation by an
utside organization does not necessarily imply endorsement.
he document was reviewed by four official representatives
rom the ACCF, and AHA; organizational review by the
AIP and SCCT, as well as 14 content reviewers. This
ocument was approved for publication by the governing
odies of ACCF and AHA in September 2006. In addition,
he governing boards of the SAIP and SCCT reviewed and
ormally endorsed this document. This document will be
onsidered current until the Task Force on CECDs revises or
ithdraws it from publication.
onsensus Statement Method
his statement builds on a previous ACC/AHA Expert
onsensus Document published in 2000 that focused onlectron beam computed tomography (CT) for diagnosis ond prognosis of coronary artery disease (1). In preparing
he present document, the Writing Committee began with
he previous report as a basis for its deliberations and
ubsequent literature review. In considering the current
tatus of research on CAC measurement and its role in
linical practice, the Expert Panel concluded that the
ajority of the research on CAC measurement in the past
years has focused on 2 areas of clinical interest: 1) Risk
ssessment in the asymptomatic patient, for the primary
urpose of modifying and potentially improving selection of
atients for risk reducing therapies, and 2) Use of CAC
easurement in symptomatic patients as a means of select-
ng patients who might require subsequent hospitalization
r additional diagnostic or invasive procedures. The Writing
ommittee also recognized that the AHA was in the
rocess of completing a scientific statement on assessment
f coronary artery disease by CT (2), and thus this Writing
ommittee’s attention was focused on evaluating clinical
spects of CAC measurement rather than on technical
ssues that are covered in the AHA statement (2). Also, the
riting Committee is aware that ACCF has recently
ublished appropriateness criteria using approaches that
iffer somewhat from those used in developing this Con-
ensus Document. Therefore, readers should be aware that
here may be slight differences in language used in this
ocument and the Appropriateness Criteria for Cardiac
omputed Tomography and Magnetic Resonance (3) doc-
ment.
At its first meeting, each member of this ACCF/AHA
riting Committee indicated any relationship with indus-
ry. Relevant conflicts of the Writing Committee and peer
eviewers are reported in Appendixes 1 and 2, respectively.
he next step in the development of this document was to
btain a complete literature review from the Griffith Re-
ource Library at the ACC concerning CAC measurement
y fast CT methods from 1998 through early 2005 (Na-
ional Library of Medicine’s Elhill System). Additional
elevant prior or subsequently published references have also
een identified by personal contacts of the Writing Com-
ittee members, and substantial efforts were made to
dentify all relevant manuscripts that were currently in press.
t the first meeting, members of the Writing Committee
ere given assignments to provide descriptions and analyses
f CAC measurement for identifying and modifying coro-
ary event risk in the asymptomatic patient, for modifying
he clinical care and outcomes of symptomatic patients
uspected of having coronary artery disease (CAD), and for
nderstanding the role of CAC measurement in selected
atient subgroups. Each individual contributor to these
arts of the document had his or her initial full written
resentation critiqued by all other members of this Writing
ommittee. Outside peer review was also undertaken before
he document was finalized.
Considerable discussion among the group focused on the
est and most proper way to assess clinical appropriateness
f tests such as CAC measurement since there have been no
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linical outcomes in either symptomatic or asymptomatic
atients. The Writing Committee agreed uniformly that the
deal assessment of cardiac tests would require clinical trials
hat utilize important patient outcomes such as improving
he quality or quantity of a patient’s life. However, recog-
izing that this standard is not available for CAC measure-
ent, the Committee considered other standards of evi-
ence in reaching a consensus opinion. A minority of the
riting Committee felt that CAC testing could not be
dvised for any clinical indication until clinical trials were
vailable to show benefit on actual patient outcomes. How-
ver, the majority of the Writing Committee felt that this
tandard of evidence is rarely applied in assessment of
ardiac testing appropriateness. Therefore, the majority
osition presented here reflects the concept that prognostic
esting such as CAC measurement can be considered
easonable where there is evidence that the test results can
ave a meaningful impact on medical decision-making.
ntroduction to CAC Measurement
oronary arterial calcification is part of the development of
therosclerosis, occurs almost exclusively in atherosclerotic
rteries, and is absent in the normal vessel wall (4–6).
oronary artery calcification occurs in small amounts in the
arly lesions of atherosclerosis that appear in the second and
hird decades of life, but it is found more frequently in
dvanced lesions and in older age. Although there is a
ositive correlation between the site and the amount of
oronary artery calcium and the percent of coronary luminal
arrowing at the same anatomic site, the relation is nonlin-
ar and has large confidence limits (7). The relation of
rterial calcification, like that of angiographic coronary
rtery stenosis, to the probability of plaque rupture is
nknown (8,9). There is no known relationship between
ulnerable plaque and coronary artery calcification (10).
lthough radiographically detected coronary artery calcium
an provide an estimate of total coronary plaque burden, due
o arterial remodeling, calcium does not concentrate exclu-
ively at sites with severe coronary artery stenoses (11).
Electron-beam computed tomography (EBCT) and
ulti-detector computed tomography (MDCT) are the
rimary fast CT methods for CAC measurement at this
ime. Both technologies employ thin slice CT imaging,
sing fast scan speeds to reduce motion artifact. Thirty to 40
djacent axial scans usually are obtained. A calcium scoring
ystem has been devised based on the X-ray attenuation
oefficient, or CT number measured in Hounsfield units,
nd the area of calcium deposits (12). A fast CT study for
oronary artery calcium measurement is completed within
0 to 15 min, requiring only a few seconds of scanning time.
Cardiac computed tomography has been used with in-
reasing frequency in the United States and other countries
uring the past 15 years, initially with the goal of identifying fatients at risk of having obstructive coronary artery disease
ased on the amount of coronary calcium present. However,
n the past 5 to 10 years, fast CT methods have been used
rimarily for 2 purposes: 1) to assist in coronary heart
isease (CHD) risk assessment in asymptomatic patients,
nd 2) to assess the likelihood of the presence of CHD in
atients who present with atypical symptoms which could
e consistent with myocardial ischemia.
Many technical aspects are relevant to the choice of
BCT versus MDCT, and these are beyond the scope of
his document. A related document, recently prepared by
he AHA, addresses these important technical issues (2). In
ontrast, this document focuses on clinical uses of fast CT
or CAC measurement and addresses the appropriateness of
AC measurement in defined clinical circumstances.
ole of Risk Assessment
n Cardiovascular Medicine
major focus of this Consensus Document is the role of
AC measurement in cardiovascular risk assessment. Thus,
brief overview of cardiovascular risk assessment is impor-
ant to provide a frame of reference for the material that
ollows.
Risk assessment is often regarded as a key first step in the
linical management of cardiovascular risk factors. Risk
ssessment algorithms, such as those from the Framingham
eart Study in the United States or from the Prospective
ardiovascular Münster (PROCAM) study in Germany, or
he European risk prediction system called SCORE (Sys-
emic Coronary Risk Evaluation), are among the most
ommon and widely available for estimating multi-factorial
bsolute risk in clinical practice (13). Each of these risk
ssessment algorithms, as most often used, projects 10-year,
bsolute risk, which can be considered short-term or
ntermediate-term (not lifetime) risk. These risk projections
re often regarded by policy makers and clinicians as useful
hen selecting the most appropriate candidates for drug
herapies intended to reduce risk. Cholesterol and blood
ressure guidelines in the United States and elsewhere have
ollowed the principle that the intensity of treatment should
e aligned with the severity of a patient’s risk (14,15). The
ationale behind this balance between treatment intensity
nd patient risk is that proportional risk reduction and
ost-effectiveness analyses indicate that there is greater
enefit of drug exposure when the patient’s risk is high. It
as been considered useful to divide patients into several
ategories depending on their 10-year risk estimates. Three
ommonly used categories are high risk, intermediate risk,
nd low risk. Beginning in 2004, the National Cholesterol
ducation Program (NCEP) further divided the
ntermediate-risk category into moderately high risk and
oderate risk (16). Table 1 shows the most recent NCEP
ategories of 10-year absolute risk used to stratify patients
or cholesterol-lowering therapy. This classification can be
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s blood pressure lowering.
atching Intensity of
ntervention With Severity of Risk
s previously noted, a principle of cardiovascular disease
revention that is generally accepted is that intensity of
ntervention for an individual (or population) should be
djusted to the level of baseline risk (17). The goals of this
rinciple are to optimize efficacy, safety, and cost-
ffectiveness of the intervention. The concept is most often
pplied to higher-risk individuals who are potential candi-
ates for risk-reducing drugs; but it also is an important
onsideration for lower risk individuals either in clinical
ractice or for public health strategies. For higher risk
ndividuals, intensity of intervention is best adjusted to
bsolute short-term risk; for lower risk individuals, relative
isk remains an important consideration because a high
elative risk generally translates into a high absolute risk in
he long term. This latter concept is most relevant to
ounger men and middle-aged men and women, whereas in
lder men and women, the Framingham Risk Score gener-
lly applies.
urrent Approaches to Global Risk
ssessment and to Assessment of
ncremental Risk Using New Tests
n current clinical practice, in accordance with a number of
uidelines (14,15), it is common that the first step in clinical
isk assessment is to identify any high-risk conditions that
bviate the need for further risk assessment; these mainly
nclude established atherosclerotic cardiovascular disease
ASCVD) and diabetes (see Table 1, High risk). If none of
hese high-risk conditions is present, the second step is to
dentify the presence of major risk factors (also listed in
able 1). If 2 or more major risk factors are present, one
hould then estimate the 10-year likelihood for develop-
ent of major coronary events or total cardiovascular events.
n the United States, the most-commonly used and most
xtensively validated quantitative assessment is provided by
he multivariable scoring system of the Framingham Heart
tudy. The Framingham algorithm for “hard CHD” events
able 1. Absolute Risk Categories According to National Chole
0-Year Absolute Risk Category
High risk CHD*, CHD risk equivalents†
Moderately high risk 2 major risk factors‡ plus a
Moderate risk 2 major risk factors plus a 1
Lower risk 0 to 1 major risk factor (10-ye
CHD includes history of myocardial infarction, unstable angina, stable angina, coronary artery pro
isk equivalents include clinical manifestations of non-coronary forms of atherosclerotic disease
ttacks or stroke of carotid origin or greater than 50% obstruction of a carotid artery]), diabetes,
moking, hypertension (BP greater than or equal to 140/90 mm Hg or on antihypertensive me
rst-degree relative less than 55 years; CHD in female first-degree relative less than 65 years), a
eople with 0 to 1 risk factor have a 10-year risk less than 10%, and 10-year risk assessment in p
I, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Pr
BP  blood pressure; CHD  coronary heart disease; HDL  high-density lipoprotein.ncluding myocardial infarction and cardiac death is avail- ible through the National Cholesterol Education Program
ebsite (http://hin.nhlbi.nih.gov/atpiii/calculator.asp). Fra-
ingham scoring includes the following major risk factors:
ender, total cholesterol, high-density lipoprotein (HDL)
holesterol, systolic blood pressure (or on treatment for
ypertension), cigarette smoking, and age. PROCAM scor-
ng employs a somewhat different set of risk factors: gender,
ge, low-density lipoprotein (LDL) cholesterol, HDL cho-
esterol, triglycerides, systolic blood pressure, cigarette
moking, family history, and presence or absence of diabetes
http://www.chd-taskforce.com/). The European SCORE
lgorithm uses risk factors similar to the Framingham Score.
For each of these risk assessment tools, the most powerful
isk factors are age and gender. The other risk factors can be
xamined for their additive predictive power by determining
ncrements in the area under the curve of the receiver-
perating characteristic (ROC). The area under the ROC
urve is also known as the C-statistic. An ROC analysis
lots sensitivity (fraction of true positives) versus 1-
pecificity (fraction of false positives) of a risk factor for
redicting events. ROC curves are used to evaluate the
iscrimination of a prediction, and often, the predictive
ower of a set of risk factors. If a given set of risk factors
redicted the development of cardiovascular events per-
ectly, the curve would reach 100% in the upper left corner
100% sensitivity and 100% specificity), that is, all true
ositives and no false positives. The area under the curve
ould be 100% (C-statistic  1.0). A random and useless
redictor would give a straight line at 45 degrees (C-statistic
0.5) since this would define a test where true positive rate
nd false positive rate are equal to one another at every
ossible cutoff value. In the evaluation of additional tests,
dded to the basic set of Framingham risk factors, the area
nder the curve would increase when the test provides
ncremental discrimination. The Framingham algorithm
pplied to the Framingham population generally gives a
-statistic of approximately 0.8, meaning that the proba-
ility is 80% that patients who experience CHD events will
ave a higher risk score than patients who did not experi-
nce an event. An important but unresolved issue is whether
iscovery and addition of new biochemical risk factors or
l Education Program Update, 2004
Definition of Category
ing 2 major risk factors‡ plus a 10-year risk for hard CHD greater than 20%§
ar risk for hard CHD 10% to 20%
r risk for hard CHD less than 10%
k for hard CHD usually less than 10%)§
s (angioplasty or by-pass surgery), or evidence of clinically significant myocardial ischemia. †CHD
eral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic
risk factors with 10-year risk for hard CHD less than 20%. ‡Major risk factors include cigarette
n), low HDL cholesterol (less than 40 mg/dL), family history of premature CHD (CHD in male
(men greater than or equal to 45 years; women greater than or equal to 55 years). §Almost all
ith 0 to 1 risk factor is thus not necessary. Modified with permission from Grundy SM, Cleeman
Adult Treatment Panel III guidelines. Circulation 2004;110:227–39 (16).stero
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January 23, 2007:378–402 ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoringill increase the C-statistic. In considering the role of CAC
easurement for risk assessment, a key issue is whether
iscriminative ability is improved, often as judged by an
ncrease in the C-statistic compared to that derived from
isk factors alone.
isk Assessment for Coronary Heart
isease in Asymptomatic Populations
rognosis by Coronary
rtery Calcium Measurements
n the prior ACC/AHA expert consensus document pub-
ished in 2000, only 3 reports on the prognostic capability of
AC scoring were available to develop risk assessment
ndications in asymptomatic individuals (1). At the time,
he ACC/AHA document concluded that the body of
vidence using CAC measurement to predict CHD events
as insufficient. A critical component to that recommenda-
ion was that the independent prognostic value of CAC had
ot been established. In a separate but similar evaluation
sing data published through 2002, the U.S. Preventive
ervices Task Force (USPSTF) concluded that limited
linical outcomes data were available and recommended
gainst routine screening for the detection of silent but
evere CAD or for the prediction of CHD events in low
isk, asymptomatic adults (see http://www.ahrq.gov/
ownloads/pub/prevent/pdfser/chdser.pdf).
In the past several years, however, a number of publica-
ions have reported on the incremental prognostic value of
AC in large series of patients including asymptomatic
elf-referred and population cohorts (18–22). A major
ationale for the current document is the need for an update
ncluding recent publications regarding CAC as it relates to
he estimation of CHD death or nonfatal myocardial
nfarction (MI). Although earlier evidence included the use
f “soft” endpoints including coronary revascularization as a
rimary outcome, more recent data are available on the
stimation of CHD death or MI (18–22). Models predict-
ng “hard” cardiac events (i.e., CHD death or MI) are less
ubjective and less likely to overestimate the predictive
ccuracy of CAC scoring (23).
heoretical Relationship Between
oronary Calcification and CHD Events
therosclerotic plaque proceeds through progressive stages
here instability and rupture can be followed by calcifica-
ion, perhaps to provide stability to an unstable lesion (8).
s the occurrence of calcification reflects an advanced stage
f plaque development, some researchers have proposed that
he correlation between coronary calcification and acute
oronary events may be suboptimal based largely on angio-
raphic series (11). In order to understand this apparent
onflict between the stability of a calcified lesion and CHD
vent rates, one must recognize the association between
therosclerotic plaque extent and more frequent calcified end non-calcified plaque (24). That is, patients who have
alcified plaque are also more likely to have non-calcified or
soft” plaque that is prone to rupture and acute coronary
hrombosis (24). It is the co-occurrence of calcified and
on-calcified plaque that provides the means for estimating
cute coronary events. Furthermore, although CAC detec-
ion cannot localize a stenotic lesion or one that is prone to
upture, CAC scoring may be able to globally define a
atient’s CHD event risk by virtue of its strong association
ith total coronary atherosclerotic disease burden, as shown
y correlation with pathologic specimens (1,24).
pproaches to Technology
ssessment in CHD Screening
major criterion utilized in many technology assessments
as been that a screening test must have a high level of
vidence on the effect of screening on actual health out-
omes, such as fewer events, extended life, or better quality
f life. This type of analysis requires research detailing an
mprovement in either quantity or quality-of-life years as a
esult of the screening procedure. An example of a high level
f such evidence was recently published on screening for
bdominal aortic aneurysm (AAA) (25). Using this exam-
le, a meta-analysis reported reduced mortality in random-
zed trials of AAA screening. These results allowed for favor-
ble support of AAA screening by the USPSTF resulting in a
lass B recommendation (i.e., evidence includes consistent
esults from well-designed, well-conducted studies in rep-
esentative populations that directly assess effects on health
utcomes) (26). Lack of similar controlled clinical trial
vidence played a central role in the conclusion by the
SPSTF not to support CHD screening using CAC
easurement (see http://www.ahrq.gov/downloads/pub/
revent/pdfser/chdser.pdf).
Although no studies have shown a net effect on health
utcomes of CAC scoring (27), at least one randomized
rial is nearing completion (Early Identification of Subclin-
cal Atherosclerosis using NoninvasivE Imaging Research
EISNER]). However, the concept of matching treatment
ntensity to the degree of cardiovascular risk suggests that
fforts to identify the most accurate approach to risk
tratification is an initial and critical step that should aid in
he best selection of treatment options for patients at risk for
ardiovascular disease.
ystematic Reviews and Meta-Analyses
n the sections that follow, we review recent evidence on the
rognostic value of CAC and include data from one recent
ystematic review. A comprehensive data synthesis on this
ubject was published by Pletcher et al. (23) evaluating the
rognostic value of CAC from 4 studies published through
002 meeting quality-based inclusion criteria. Articles were
onsidered for that meta-analysis if they evaluated the
rognostic value of CAC in asymptomatic individuals and
lso presented data on CHD events. Based on a random-
ffects model, the summary relative risk ratios were 2.1 (for
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han 400) as compared to patients with a score of 0 (p less
han 0.0001). This meta-analysis (23) offers support for the
oncept that there is a linear relationship between CAC and
HD events, but the analysis did not address whether CAC
easurement is incremental to Framingham Risk Score
FRS) for CHD risk prediction.
ata Quality Issues
lack of rigor in study methodology was a focus of the 2000
CC document (1). A detailed review of the quality of the
ublished data on the prognostic value of CAC was also
ublished by Pletcher et al. (23) noting significant hetero-
eneity in study quality with often a lack of blinded outcome
djudication, greater use of categorical or historical risk
actors, and variable tomographic slice thickness (3 vs. 6
m) contributing to an overestimation of the relative risk of
vents by CAC measurements. For example, the relative
isk ratio was significantly higher for CAC of 101 to 400
p  0.01) and greater than 400 (p  0.004) when
elf-reported or historical risk factors were employed in a
redictive model as compared with measured risk factor
ata. The clinical implication of this distinction is that
hysicians interpreting these results may overvalue CAC
cores as substantially more predictive than traditional risk
actors.
Evaluation of more recent publications indicates that
ome of the important methodological limitations of earlier
eports have been addressed. Notably, more recent publica-
able 2. Quality Assessment Criteria for Evaluation of Reports
Criteria Points Assigned by Definition
. Retrospective vs. prospective
study
1  Retrospective
2  Prospective
. Potential for referral bias 0  Clinically referred patients
1  Unselected cohort
2  Population sample
. Reporting CAC by CHD death
or MI
1  No
2  Yes
. Reporting of results by gender
or ethnicity
0  No
1  Gender only
2  Ethnicity only
3  Both
. Sample size greater than 1000 0  No
1  Yes
. Potential for limited challenge 1  No reporting of CAC outcomes
in low- to high-risk global risk
scores
2  Reporting of CAC outcomes in
low- to high-risk global risk
scores
. Risk factor reporting 1  Historical only
2  Measured in subset
3  Measured in all subjects
. Covariate or risk-adjusted
outcomes
Risk Factors
otal score (total possible  16)
AC  coronary artery calcification; CHD  coronary heart disease; MI  myocardial infarction.ions report the independent prognostic value of CAC in sultivariable models including measured risk factor data
18,19,22). Larger sample sizes have also resulted in im-
roved precision in risk prediction models. However, issues
f selection or referral bias when using patient cohorts
emain pertinent and are likely to have resulted in an
verestimation of risk when based on clinical cohorts as
ompared with population samples (20,22). It is important
o recognize that relative risk ratios from patient cohorts
ave generally been higher than from studies conducted in
opulation samples even when the overall direction of the
rognostic findings has been concordant.
nclusion Criteria and Endpoint
efinitions for the Present Analysis
he current document focuses on the ability of CAC
coring to estimate CHD death or MI. This approach
llows for a comparison of the expected annual event rates
ased on the FRS. The FRS estimates that annual rates of
HD death or MI are less than 1.0% for low risk, 1.0% to
.0% for intermediate risk (Table 1), and greater than 2.0%
or high risk. When multiple publications have been re-
orted from the same cohort study (1,4,5,33–36), we
mploy here only the most recent report in the current
nalysis (19,20).
The inclusion criteria for this analysis are: 1) data not
reviously reported in the 2000 document (1); 2) published
eries on the prognostic value of CAC in asymptomatic
ohorts reported since 2002; 3) endpoint data must be
eported on the outcome of CHD death or MI over a
e Prognostic Value of CAC
dos Greenland Arad Taylor Vliegenthart LaMonte
2 2 2 2 1
1 1 1 2 0
2 1 2 2 2
0 0 1 0 1
1 1 1 1 1
2 1 2 2 1
3 2 3 3 1
2 1 2 2 1
13 8 14 14 8on th
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January 23, 2007:378–402 ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoringnd 4) data extraction must allow for the calculation of
nivariable relative risk ratios and must also include risk-
djustment for traditional cardiac risk factors (e.g., age,
ender, cholesterol, hypertension, etc.) or the FRS.
Two committee members (AJT, LJS) evaluated the
uality of each included report with the results of this
nalysis being included in Table 2. The quality assessment
riteria included: 1) documentation of prospective data
ollection; 2) inclusion of self-referred patient series or from
population sample; 3) reporting of CHD events; 4)
eporting of outcome data by gender and ethnicity; 5)
ample size greater than 1000 individuals; 6) avoiding
otential for limited challenge (i.e., an inclusion of very low
o very high-risk patients resulting in a wide spread in the
utcome results) by not reporting data within strata of
linical risk; 7) reporting measured versus historical or
elf-reported risk factor data; and 8) reporting univariable
nd multivariable prognostic models (i.e., ascertaining the
ncremental value of CAC scores). A review of the high-
ighted reports reveals that all studies identified for inclusion
ere of at least moderate-high quality.
rognostic Value of CAC Scores From
ublished Reports From 2003–2005
everal recent cohorts have been published including pro-
pective observational registries in predominantly male,
ounger and middle-aged (18), unselected (19) and older-
ged, higher risk (20) asymptomatic cohorts. A self-referred
igure 1. Meta-Analysis on the Prognostic Value of CACS
elative risk (RR) ratios (95% confidence intervals [CI]) in six published reports (18–atient series of 8855 asymptomatic adults was also included un this analysis (21). A recent population sample was also
ublished and included 1795 subjects greater than or equal
o 55 years of age who were prospectively enrolled in the
otterdam coronary calcium study (22). Finally, the prog-
ostic value of CAC scores was recently reported from a
arge series of 10 746 men and women aged 22 to 96 years
ho underwent a preventive health examination at the
ooper Clinic in Dallas, Texas (28).
Using a random-effects model, an analytical approach
requently applied to observational data such as that re-
orted in the CAC series, Figure 1 reports on the univari-
ble and summary (weighted average) relative risk ratios
rom 6 recently published reports in 27 622 patients (n 
95 CHD death or MI). This figure reports the summary
elative risk ratio of 4.3 (95% confidence interval [CI] 3.5
o 5.2) for any measurable calcium as compared with a
ow-risk CAC (generally using a score of 0) (p less than
.0001). These data imply that the 3 to 5 year risk of any
etectable calcium elevates a patient’s CHD risk of events
y nearly 4-fold (p less than 0.0001). Importantly, patients
ithout detectable calcium (or a CAC score  0) have a
ery low rate of CHD death or MI (0.4%) over 3 to 5 years
f observation (n  49 events/11 815 individuals).
As can be further seen in Figure 1, considerable variability
xisted in the relative risk ratios across the 6 reports which
an, in part, be attributed to variability in the grouping of
AC scores and in the representation of younger individ-
). CACS  coronary artery calcification score.als and women within each of the risk subsets. In the most
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ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoring January 23, 2007:378–402ecent report from the Cooper Clinic, different CAC ranges
n risk groupings were applied for women and men (28).
oreover, both the Walter Reed and Cooper Clinic series
valuated younger asymptomatic cohorts while the Rotter-
am study limited enrollment to individuals greater than or
qual to 55 years of age (18,22).
The summary relative risk ratios in Figure 2 reveal an
ncremental relationship where higher CAC scores are
ssociated with higher event rates and higher relative risk
atios. In this figure, a mild risk CAC score (with scores
anging from 1 to 112) was associated with an elevation in
HD death or MI risk with a summary relative risk ratio of
.9 (95% CI  1.3 to 2.8, p  0.001). This mild risk
rouping was more often reported in younger populations
ndergoing preventive health screenings (18,28).
With even higher CAC scores, the 3 to 5 year event rates
ncreased substantially. For scores ranging from 100 to 400,
he summary relative risk ratio was 4.3 (95% CI  3.1 to
.1) when compared to patients with no detectable coronary
alcium (p less than 0.0001). For the high (CAC scores of
00 to 1000) and very high (greater than 1000) risk CAC
cores, pooled CHD death or MI rates were 4.6% and 7.1%
t 3 to 5 years after CAC testing, resulting in relative risk
atios of 7.2 (95% CI  5.2 to 9.9, p less than 0.0001) and
igure 2. RR Ratios According to Level of Risk for CACS, From Av
verage risk includes Arad et al. (19), Greenland et al. (20), LaMonte et al. (28), an
nte et al. (28), Taylor et al. (18), and Vliegenthart et al. (22). High risk includes Ara
art et al. (22). Very high risk includes Vliegenthart et al. (22). *Low-risk N often inc
4 would use the same referent low-risk group comparison). CACS  coronary artery
able 3. Recent Published Observational Cohort Studies Evalua
rognostic Value of Coronary Calcium Measurements in Publish
Risk
Subset Year N
Historical or
Measured Risk
Factor Data Univ
ondos 2003 8855 Historical 5.8, p  0
reenland 2004 1461 Measured 3.9, p  0
rad 2005 1293 Measured 26.2, p 
aylor 2005 1639 Measured NR, p  0
liegenthart 2005 1795 Measured 8.2, p  0
aMonte 2005 10 746 Historical 1.6 (men)
p  0.0
For RR, a linear trend is presented if not indicated otherwise. Kondos: for any detectable CAC
ontinuous measure in the multivariable model; Arad: univariable RR is for score greater than or
nly and for any CAC score versus CAC  0; Vliegenthart: multivariable is across a range of CAC
nivariable reported separately for men (1.6) and women (1.3), multivariable RR were NR but s
djustment was not specified but noted as significant.
BMI  body mass index; CAC  coronary artery calcification; CHD  coronary heart disease; FRS  F
R  not reported; RR  relative risk.0.8 (95% CI  4.2 to 27.7, p less than 0.0001) when
ompared to the low-risk group (CAC score  0) as
eference.
ndependent Prognostic Value of
AC Scores Over Cardiac Risk Factors
necessary criterion for establishing a high degree of
redictive accuracy for CAC measurements is the establish-
ent of the independent contribution of CAC above and
eyond risk factor data alone (29). Recent reports have
ncluded univariable and multivariable models that have
valuated the independent contribution of CAC in models
valuating risk factors or the FRS (Table 3). From the St.
rancis Heart Study, measured risk factor data were avail-
ble in 1293 of the total enrolled cohort of 4903 asymp-
omatic individuals. In univariable (p less than 0.0001) and
ultivariable (p  0.01) models estimating CHD events at
.3 years of follow-up, CAC scores were independently
redictive of CHD outcome above and beyond both histor-
cal and measured risk factors (19). The CAC scores were
lso predictive of outcome in a multivariable model contain-
ng high-sensitivity C-reactive protein (18), similar to a
revious report by Park et al. (30). Several reports have also
valuated the independent prognostic contribution of CAC
Risk to Very High Risk
r et al. (18). Moderate risk includes Arad et al. (19), Greenland et al. (20), LaM-
l. (19), Greenland et al. (20), Kondos et al. (21), LaMonte et al. (28), and Vliegent-
multiple comparisons from a single series (e.g., Taylor CACS of 1 to 9 and 10 to
cation score; CI  confidence interval; RR  relative risk.
the Independent
eports From 2003 to 2005
le RR* Multivariable RR*
Model Controlling for
Additional Variables Besides
That Contained in the FRS:
3.9, p  0.01
1.3, p  0.001‡
1 NR, p  0.01 HsCRP
11.8, p  0.002 Family history of CHD
3.2–10.3, p  0.03 Family history of MI and BMI
.3 (women), NR§
only; Greenland: for CAC greater than 300 versus CAC  0 for univariable RR, evaluated as a
400, multivariable RR was NR; Taylor: univariable RR was NR, multivariable risk ratio is in men
01 to greater than 1000; LaMonte: risk factors measured in a clinical subset of 3619 subjects;
be similar to age-adjusted models. †For men only. ‡For intermediate to high FRS. §p for riskerage
d Taylo
d et ating
ed R
ariab
.001†
.001
0.000
.0001
.01
and 1
001
in men
equal to
from 1
tated toramingham Risk Score; HsCRP  high-sensitivity C-reactive protein; MI  myocardial infarction;
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January 23, 2007:378–402 ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoringn multivariable models that controlled for other cardiovas-
ular risk markers, including risk factors not in the FRS,
uch as a family history of premature CHD (18,22) or body
ass index (22) (Table 4).
redictive Accuracy in
atients With an Intermediate FRS
he concept of Bayesian theory provides a framework to
valuate the expected relationship between the predictive
alue of CAC score in individuals with low- to high-risk
RS. As defined by Bayesian theory, a test’s post-test
ikelihood of events is partially dependent upon a patient’s
retest risk estimate. Thus, for patients with a low risk FRS
ery few events would be expected during follow-up and the
esulting post-test risk estimate for patients with an abnor-
al CAC score would be expected to remain low. Several
eports have noted that the use of CAC score in low-risk
opulations is not useful in modifying prediction of out-
ome (20,21). Greenland et al. (20) reported that a high
AC score was predictive of high risk among patients with
n intermediate-high FRS greater than 10% (p less than
.001) but not in patients with a low risk FRS (i.e., score
ess than 10%). In this report from the South Bay Heart
atch study, only 1 CHD event was noted in 98 patients
ith a low risk FRS. This report demonstrates the impor-
ance of considering the underlying hazard in selecting
ptimal cohorts for whom CAC testing will be of greater
alue.
In addition, the recent data provide support for the
oncept that use of CAC testing is most useful in terms of
ncremental prognostic value for populations with an inter-
ediate FRS (29). In a secondary analysis of patients with
n intermediate FRS from 4 reports (19,20,22,28), annual
HD death or MI rates were 0.4%, 1.3%, and 2.4% for each
ertile of CAC score where scores ranged from less than
00, 100 to 399, and greater than or equal to 400,
espectively (19,20) (Fig. 3). From this analysis,
ntermediate-risk FRS patients with a CAC score greater
han or equal to 400 (Fig. 3) would be expected to have
able 4. Predictive Accuracy of CAC for Estimation of CHD De
nd Risk-Adjusted Multivariable Models Controlling for the Fram
Risk
Subset Year N
Relative Risk (95% CI)
for High Risk CAC
M
Pr
reenland 2004 1461 —
rad 2005 1293 —
aylor 2005 1639 4.8 (1.1–20.4)
liegenthart 2005 1795 3.9 (1.4–11.1)
aMonte 2005 3619 15.9 (2.2–114.7)
Modestly strong predictor.  Moderately strong predictor.  Strong predictor.
CAC  coronary artery calcification; CHD  coronary heart disease; CI  confidence interval;vent rates that place them in the CHD risk equivalent dtatus (event rate greater than or equal to 20% over 10
ears (31).
uture Research Needs
he vast majority of prognostic evidence has been reported
sing an evaluation of risk stratification with absolute
easurements of the CAC score. However, some earlier
eports applied gender- and age- percentile rankings that
ay have greater intuitive appeal and understanding for
atient education. As such, the percentile rankings have the
otential for greater clinical applicability and, therefore,
tilization. Only one report has evaluated the comparative
redictive ability of absolute CAC scores versus the percen-
ile scores. These investigators noted an improvement in
isk detection using percentile ranks (32). An advantage to
he use of percentiles is that it has been integrated into the
CEP guidelines where more aggressive care was recom-
ended for patients with a 75th percentile ranking or
igher (31). Thus, more information on percentile rankings
or prognosis is needed; however, very few research groups
ave consistently reported CAC data according to percen-
ile ranking. In addition, in our review of the current
ublished evidence, the relative risk ratio for a high risk
AC measurement is higher for clinical registries as com-
ared with population studies (relative risk  19.3 vs. 5.0);
uggesting an overestimation in risk due to selection bias
18–20,22). Data from the ongoing Multi-Ethnic Study of
therosclerosis (MESA) should allow for more accurate
isk estimation of CAC scores as based on a prospectively-
erived large population sample (33).
ummary
ince 2000, when the last ACC CECD report on CAC
easurement was published, there has been growing evi-
ence on the use of CAC in better-studied cohorts of
atients and asymptomatic individuals. CAC scoring has an
ncreasingly high level of quality evidence on its role in risk
tratification of asymptomatic patients. Recent evidence is
upportive that measurement of CAC is predictive of CHD
r Myocardial Infarction Including Unadjusted
am Risk Score (FRS) and Other Risk Markers
justed
ncluding
as a
r of CHD
or MI
Multivariable Model Including
CAC  FRS and Other Novel
Risk Markers As Predictors
of CHD Death or MI
Additional Factors Not
Novel Risk Markers
Included in the
Multivariable Model
  —
  HsCRP
  Family history of CHD
 Family history of MI
and body mass
index
 
 high-sensitivity C-reactive protein; MI  myocardial infarction.ath o
ingh
Unad
odel I
CAC
edicto
Death




eath or MI at 3 to 5 years. Current evidence also suggests
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ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoring January 23, 2007:378–402hat the use of CAC is independently predictive of outcome
ver and above traditional cardiac risk factors. Published
eports have largely been derived from patient cohorts where
eferral bias is operational resulting in an overestimation of
HD death or MI risk estimates. Upcoming data from the
ESA study may be helpful to devise population screening
trategies for women and in non-whites. The MESA data
ill also be useful in validating predictive capability by
thnicity and across a broad age range of asymptomatic
eople. Data employing direct comparisons of CAC mea-
urement versus other imaging modalities or biomarkers are
enerally not available.
The consensus of the Committee was that the body of
vidence is supportive of recommendations from the
SPSTF that unselected screening is of limited clinical
alue in patients who are at low risk for CHD events,
ypically estimated using a low FRS less than 1.0% per year
see http://www.ahrq.gov/downloads/pub/prevent/pdfser/
hdser.pdf).
A subset analysis of the predictive accuracy of CAC in
atients with an intermediate FRS reveals that for a score
reater than or equal to 400, the patient’s 10-year CHD risk
ould achieve risk equivalent status similar to that noted
ith diabetes or peripheral arterial disease (31). Thus,
linical decision-making could potentially be altered by
AC measurement in patients initially judged to be at
ntermediate risk (10% to 20% in 10 years).
The accumulating evidence suggests that asymptomatic
ndividuals with an intermediate FRS may be reasonable
andidates for CHD testing using CAC as a potential
eans of modifying risk prediction and altering therapy. On
he other hand, there is little to be gained by testing with
AC in patients with a low FRS. Furthermore, patients
igure 3. Estimated Annual Risk of CHD Death or MI Rate
ate shown is by tertile of the Agatston score in patients at intermediate coronary h
core (FRS) or greater than 1 cardiac risk factor. Intermediate FRS was defined as f
28), greater than 1 cardiac risk factor; and Arad et al. (19) 10% to 20%. CACS  coith a high FRS should be treated aggressively consistent mith secondary prevention goals based upon the current
CEP III guidelines and thus should not require additional
esting, including CAC scoring, to establish this risk eval-
ation (31). Additionally, the current CAC literature does
ot provide support for the concept that high-risk asymp-
omatic individuals can be safely excluded from medical
herapy for CHD even if CAC score is 0.
ole of CAC Scoring in
ssessment of Symptomatic Patients
iagnosis of Coronary Stenosis in
atients With Possible CHD by CAC
he utility of coronary artery calcium measurement in
ymptomatic patients has been widely studied and discussed
n depth in the previous ACC/AHA statement (1). It was
lso extensively reviewed in the recent American Heart
ssociation Cardiac Imaging Committee Consensus State-
ent—The Role of Cardiac Imaging in the Clinical Eval-
ation of Women With Known or Suspected Coronary
rtery Disease (34). One conclusion of these reports was
hat a positive CT study (defined as presence of any CAC)
s nearly 100% specific for atheromatous coronary plaque
34,35). Since both obstructive and non-obstructive lesions
an have calcification present in the intima, CAC is not
pecific for obstructive coronary disease.
In the symptomatic patient, CAC has been evaluated as
noninvasive diagnostic technique for detecting obstructive
AD. To define its test characteristics and to compare it
ith other noninvasive tests, a meta-analysis was performed
nd published in the previous ACC/AHA consensus state-
sease (CHD) event risk using definitions of an intermediate Framingham Risk
Greenland et al. (20) 10% to 20%; Vliegenthart et al. (22) 20%; LaMonte et al.
artery calcium score; MI  myocardial infarction.eart di
ollows:ent (1). In the previous meta-analysis, a total of 3683
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iagnostic accuracy of CAC measurement (1). Inclusion
riteria were: diagnostic catheterization for patients without
rior history of coronary disease or prior cardiac transplan-
ation. Patients were symptomatic and referred to the
ardiac catheterization laboratory for diagnosis of obstruc-
ive CAD. On average, significant coronary disease (greater
han 50% or greater than 70% stenosis by coronary angiog-
aphy) was reported in 57.2% of the patients. Presence of
AC was reported on average in 65.8% of patients (defined
s a score greater than 0 in all but one report). The
eighted-average or summary odds were elevated 20-fold
ith a positive CAC (score greater than 0) (95% CI 4.6 to
7.8). Additional summary odds ratios were also calculated
ith various anatomic and calcium score cut points. For
etection of minimal, greater than 50%, and greater than
0% stenosis at cardiac catheterization, the summary odds
ncreased from 6.8-fold (95% CI 3.0 to 15.6) to 16.4-fold
95% CI 5.1 to 53.1) to 50-fold (95% CI 24.1 to 103.0);
hat is, the odds of significant coronary disease increased
hen greater angiographic lesion thresholds were used for
ignificant disease (although the confidence bounds wid-
ned). Higher coronary calcium scores increased the likeli-
ood of detecting significant coronary disease (greater than
0% or greater than 70% luminal stenosis). A threshold of
etectable calcium or a score greater than 5 was associated
ith an odds of significant disease of 25.6-fold (95% CI 9.6
o 68.4).
Schmermund et al. (36) examined 291 patients with
uspected CHD who underwent risk factor determination
s defined by the NCEP, CAC measurement, and clinically
ndicated coronary angiography. A simple noninvasive index
NI) was constructed as the following: log(e)(LAD score)
og(e)(LCx score)  2[if diabetic]  3[if male]. Receiver-
perating characteristic curve analysis for this NI yielded an
rea under the curve of 0.88  0.03 (p less than 0.0001) for
eparating patients with, versus without, angiographic
-vessel and/or left main CAD. Various NI cutpoints
emonstrated sensitivities from 87% to 97% and specificities
rom 46% to 74%. Guerci et al. (37) studied 290 men and
omen undergoing coronary arteriography for clinical indi-
ations. A coronary calcium score greater than 80 (Agatston
ethod) was associated with an increased likelihood of any
oronary disease regardless of the number of risk factors,
nd a coronary calcium score greater than or equal to 170
as associated with an increased likelihood of obstructive
oronary disease regardless of the number of risk factors
p less than 0.001). Kennedy et al. (35) studied 368
ymptomatic patients undergoing cardiac catheterization.
y multivariate analysis, only male sex and coronary calci-
cation were significantly related to extent of angiographic
isease. Receiver-operating characteristic curve analysis
howed that the amount of coronary calcium was a signif-
cantly better discriminator of disease than were the stan-
ard risk factors. In all three studies, CAC scoring improved
iagnostic discrimination over conventional risk factors in ohe identification of persons with angiographic coronary
isease.
More recently, large multi-center studies have been
eported using fast CT for diagnosis of obstructive CAD in
ymptomatic persons (n  1851), who underwent coronary
ngiography for clinical indications. Study prediction mod-
ls were designed to be continuous, adjusted for age and sex,
orrected for verification bias, and independently validated
n terms of their incremental diagnostic accuracy. The
verall sensitivity was 95%, and specificity was 66% for
oronary calcium score to predict obstructive disease on
nvasive angiography. The logistic regression model exhib-
ted excellent discrimination (receiver operating character-
stic curve area of 0.84  0.02) and calibration (chi-square
oodness of fit of 8.95, p  0.44) (38). Increasing the
ut-point for calcification markedly improved the specific-
ty, but decreased the sensitivity. In the same study, increas-
ng the CAC cutpoint to greater than 80 decreased the
ensitivity to 79% while increasing the specificity to 72%. In
nother large study (n  1764) comparing CAC to angio-
raphic coronary obstructive disease, use of a CAC score
reater than 100 resulted in a sensitivity of 95% and a
pecificity of 79% for the detection of significant obstructive
isease by angiography (39). Summing these 2 large studies
n  3615) leads to an estimated sensitivity of 85%, with a
pecificity of 75%. There is some concern, due to study
esign, that these studies (similar to validation of many
on-invasive cardiovascular tests) are subject to verification
ias, which could raise the sensitivity and lower the speci-
city. A large study, evaluating consecutive symptomatic
ersons undergoing cardiac catheterization, addresses this
oncern. 2115 consecutive symptomatic patients (n  1404
en; mean age  62, SD  19 years old) with no prior
iagnosis of CAD were included in this study. These
atients were being referred to the cardiac catheterization
aboratory for diagnosis of possible obstructive coronary
rtery disease, without knowledge of the CAC scan results.
he scan result did not influence the decision to perform
ngiography. Overall sensitivity was 99%, and specificity
as 28% for the presence of any coronary calcium being
redictive of obstructive angiographic disease. With volume
alcium score greater than 100, the sensitivity to predict
ignificant stenoses on angiography decreased to 87% and
he specificity increased to 79% (40).
omparison With Other Tests for CHD Diagnosis. It is
ppropriate to compare CAC scoring by fast CT with the
lder more mature diagnostic modalities. The equipment
nd personnel for performing stress electrocardiography,
yocardial perfusion imaging, and echocardiography are
eadily available. The electrocardiographic (ECG) exercise
est, like the echocardiogram, can be performed in the
octor’s office and does not require exposure to radiation.
xercise ECG Test. Gianrossi et al. (41) investigated the
eported diagnostic accuracy of the exercise ECG for CAD
bstructive disease in a meta-analysis. One hundred forty-
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ients who underwent both coronary angiography and exer-
ise testing were summarized. Wide variability in sensitivity
nd specificity was found (mean sensitivity was 68%, with a
ange of 23% to 100% and a standard deviation of 16%;
ean specificity was 77%, with a range of 17% to 100% and
standard deviation of 17%).
yocardial Perfusion Imaging and Stress Echocardi-
graphy. Fleischmann et al. (42) reviewed the contempo-
ary literature to compare the diagnostic performance of
xercise echocardiography and exercise nuclear perfusion
canning in the diagnosis of CAD. Forty-four articles (not
nique patient data sets) met inclusion criteria: 24 reported
xercise echocardiography results in 2637 patients with a
eighted mean age of 59 years, of whom 69% were men,
6% had angiographic coronary disease, and 20% had prior
yocardial infarction; and 27 reported exercise SPECT in
237 patients, of whom 70% were men, 78% had angio-
raphic coronary disease, and 33% had prior myocardial
nfarction. In pooled data weighted by the sample size of
ach study, exercise echocardiography had a sensitivity of
5% (95% CI 83% to 87%) with a specificity of 77% (95%
I 74% to 80%). Exercise perfusion yielded a similar
ensitivity of 87% (95% CI 86% to 88%) but a lower
pecificity of 64% (95% CI 60% to 68%) (42).
There are more recent direct comparison studies available
n patients who underwent both CAC measurements, as
ell as either exercise electrocardiography and/or nuclear
maging, with results compared to cardiac catheteriza-
ion. Shavelle et al. (43) reported 97 patients who
nderwent technetium stress testing (technetium-stress),
readmill-ECG, and fast CT coronary scanning within 3
onths of invasive coronary angiography for the evalua-
ion of chest pain. The relative risk of obstructive
ngiographic CAD for an abnormal test was higher for
ast CT CAC scores (4.53) than either treadmill-ECG
1.72) or technetium-stress (1.96). The accuracy of fast CT
as significantly higher (80%) than either treadmill testing
71%) or technetium-stress (74%) in the diagnosis of ob-
tructive CAD. The combination of a positive CAC (cal-
ium score greater than 0) and abnormal treadmill-ECG
aised the specificity to 83% for obstructive disease).
Kajinami et al. (44) evaluated 251 symptomatic patients
ho underwent coronary angiography, fast CT, ECG, and
hallium exercise testing. The ECG and thallium exercise
ests had overall sensitivity of 74% and 83%, respectively,
nd specificity of 73% and 60%, respectively. The sensitivity
nd specificity of CAC scoring were 77% and 86%, respec-
ively. In a related study (45), 150 patients underwent
hallium stress testing, fast CT, and coronary angiography.
he relative risk of an abnormal thallium stress test was 3.5,
ompared to 14.9 for an elevated CAC score as detected by
ast CT. Yao et al. (46) compared technetium-99m single-
hoton emission tomography and fast CT in 51 patients
ith suspected CAD. Although differences were found oetween the 2 testing methods in patients with single-vessel
AD, the sensitivity, specificity, and accuracy were compa-
able in patients with multivessel CAD.
Schmermund et al. (47) also compared fast CT CAC
easurement to nuclear stress test results in a cohort of 308
ymptomatic patients. The association of CAC score with
ngiographically detected obstructive coronary disease re-
ained highly significant after excluding the influence of all
nterrelated risk factors and SPECT variables (p less than
.0001).
Data also support a complementary role for coronary
alcium and myocardial perfusion scanning (MPS) mea-
urements. He et al. (48) noted a threshold phenomenon
ith almost no observable myocardial hypoperfusion among
atients with a CAC score less than 100 and with a marked
ncrease in the frequency of an abnormal MPS in patients
ith high CAC values (greater than 100) (48). A recent
tudy of 1195 patients who underwent CAC measurement
nd MPS assessment demonstrated that CAC was the most
owerful predictor of an ischemic nuclear test, and that less
han 2% of all patients with CAC less than 100 had positive
PS studies (49). CAC score, due to its high sensitivity for
ow-limiting CAD, may be useful as a filter prior to
nvasive coronary angiography or stress nuclear imaging.
ther Uses of CAC Measurement in Symptomatic
ersons. Another potential use of CAC is to determine the
tiology of cardiomyopathy. The clinical manifestations of
atients with ischemic cardiomyopathy are often indistin-
uishable from those patients with primary dilated cardio-
yopathy. One large study in 120 patients with heart failure
f unknown etiology demonstrated the presence of CAC
as associated with 99% sensitivity for ischemic cardiomy-
pathy (50). Another study also demonstrated similarly high
ensitivity using fast CT to differentiate ischemic from
on-ischemic cardiomyopathy (51). This methodology has
een demonstrated to be more accurate than echocardiog-
aphy and MPS techniques in direct-comparison studies in
his population (52,53). Additional comparative prognostic
nd diagnostic evidence is required to evaluate the role of
T as compared with conventional stress imaging tech-
iques, as well as an assessment developing marginal cost
ffectiveness models.
Another potential application of CAC scoring relates to
he triage of chest pain patients. Three studies have docu-
ented that CAC is a rapid and efficient screening tool for
atients admitted to the emergency department with chest
ain and nonspecific electrocardiograms (54–56). These
elatively small-scale studies (with sample sizes ranging
rom 105 to 192) showed sensitivities of 98% to 100% for
dentifying patients with acute MI and very low subsequent
vent rates for persons with negative tests. The high
ensitivity and high negative predictive value may allow
arly discharge of those patients with non-diagnostic ECG
nd negative CAC scans (scores  0). Long term follow-up
f one patient cohort demonstrated a very low risk of events
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January 23, 2007:378–402 ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoringn patients without demonstrated CAC at the time of
mergency room visit (54). However, unlike the case with
valuations of asymptomatic patients (20), prognostic stud-
es of CAC in symptomatic patients have generally been
imited by biased samples (e.g., patients referred for invasive
oronary angiography) and small numbers of hard outcome
vents. Future studies should include larger numbers of
atients and should allow for adequate length of follow-up
nd assessment of larger numbers of hard endpoint events,
specially all-cause mortality and myocardial infarction (57).
ummary. For the symptomatic patient, exclusion of mea-
urable coronary calcium may be an effective filter before
ndertaking invasive diagnostic procedures or hospital ad-
ission. Scores less than 100 are typically associated with a
ow probability (less than 2%) of abnormal perfusion on
uclear stress tests (48,49), and less than 3% probability of
ignificant obstruction (greater than 50% stenosis) on car-
iac catheterization (38,39). The presence of CAC by fast
T is extremely sensitive for obstructive (greater than 50%
uminal stenosis) CAD (95% to 99%), but has limited
pecificity. CAC studies of over 7600 symptomatic patients
emonstrate negative predictive values of 96% to 100%,
llowing for a high level of confidence that an individual
ith no coronary calcium (score  0) has no obstructive
ngiographic disease (38–40).
In direct-comparison studies, CAC detection in the
ymptomatic person has been shown to be comparable to
uclear exercise testing in the detection of obstructive CAD.
iven the prognostic information that is implicit in exercise
apacity, even when it is combined with imaging, fast CT
tarts with a disadvantage compared with existing modali-
ies in symptomatic patients who can exercise. Anatomic
esting, such as cardiac CT (whether with contrast in the
orm of CT angiography or without contrast, such as CAC
ssessment), should be relegated to second line testing or
onsidered when functional testing is either not possible or
ndeterminate. The accuracy of CAC is not limited by
oncurrent medication, the patient’s ability to exercise,
aseline wall motion, or electrocardiogram abnormalities.
se of Coronary CT for
ssessment of Progression or
egression of Coronary Atherosclerosis
erial noninvasive monitoring of calcified atherosclerosis
sing CAC measurement has been proposed as a means of
onitoring medical treatment for CAD as well as assessing
hange in CVD prognosis (58). The validity of serial
oronary calcium measurements as a method to monitor
rogression of atherosclerosis requires: 1) that progression
f coronary calcium has biologic relevance to atherosclerosis
ctivity; 2) that progression of coronary calcium can be
etected relative to inter-test variability; 3) that changes in
oronary calcium severity have prognostic relevance; and 4) shat modification of cardiovascular risk factors modulates
he progression of coronary calcium. Each of these points is
ubsequently discussed.
iologic Relevance of
oronary Atherosclerosis Progression
he extent of coronary calcium found on fast CT is broadly
elated to plaque burden, but there is a high degree of
ite-to-site variability in the presence and extent of calcium
ithin any single atherosclerotic plaque. Pathology studies
ave shown that the extent of coronary calcium within
laques tends to be related to the presence of healed plaque
uptures (59). Moreover, vulnerable plaques tend to be those
ith less extensive calcium deposits frequently seen in a
potty distribution (59), a finding supported by intravascular
ltrasound studies of patients with acute coronary syn-
romes (60). The biology of progression of calcium within
therosclerosis is complex, genetically-directed, and partially
odified by drugs that have the potential to alter the
undamental biology of the calcification process. Statins, for
xample, can both inhibit and promote tissue calcification
pon interaction with different types of vascular cells (61).
The associations between CAC progression and clinical
ardiovascular risk factors are not well understood. Present
ata indicate that CAC progression is most strongly related
o the baseline CAC score with only a limited relationship
o standard cardiovascular risk factors (62,63).
ccuracy of Serial Coronary Calcium Assessments
rogression of coronary calcium is typically evaluated as a
ercentage of the baseline calcium score value. Early studies
f the inter-test variability of CAC measurements indicated
nter-scan variability as high as 25% to 50% of the calcium
core value (62,64,65). More recently, imaging protocol
efinements specific to electron beam CT scanning, includ-
ng a reduction of the electrocardiographic gating interval to
pproximately 40% to 60% of the relative risk interval, and
tilizing 3-mm slice thickness, have reduced the inter-test
ariability to 15% or less (66). The standard deviation of the
nterscan variability reported in the recent literature is
pproximately 10% (64). In contrast, annual CAC progres-
ion rates typically exceed 20% (62,64,65), thus permitting
ccurate determination of the presence or absence of true
rogression in individual patients across relatively short (1 to
year) time horizons. The ability to track CAC progression
s most accurate in patients with intermediate and higher
AC scores because the absolute error in CAC measure-
ent would approximate the actual CAC score in patients
ith low scores (CAC score 1 to 30), and even small
hanges in the absolute calcium score would be a relatively
arge fractional change.
rognostic Relevance of CAC Score Changes
here have been 3 reports from the work of Raggi and
olleagues on the relationship between changes in CAC
core and outcomes (67–69). In these studies including a
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ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoring January 23, 2007:378–402eneral population (67) analyzed by diabetic status (68) and
reatment with statins (69), subjects who suffered an MI
emonstrated an approximately 2-fold greater annual CAC
ncrease than event-free survivors. In the presence of defi-
ite CAC score progression (greater than 15%/year), there
as a significant increase in relative risk of myocardial
nfarction compared to subjects with stable scores. Notably,
he finding of CAC progression increased the associated
ardiovascular risk across all levels of CAC severity (69).
urthermore, the detection of stable CAC was associated
ith a low risk of cardiovascular events, even among those
ith extensive CAC. A major limitation of using calcium
core progression as a marker of risk is that the positive
redictive value appears to be low with substantial overlap
mong those with and without future events. Nonetheless,
erial monitoring of atherosclerosis to refine risk prediction
emains a potentially attractive hypothesis in need of ongo-
ng investigation. Confirmatory reports from screening pop-
lations are needed to assess the strength and generalizabil-
ty of these findings.
odification of CAC Progression
rogression of CAC is frequently observed across modest (3
o 7 year) time horizons to a degree primarily related to the
xtent of baseline coronary calcification (70,71). Several
harmacological interventions, including statins and cal-
ium channel blockers, have been associated with delayed
rogression of CAC. The earliest work primarily involved
tatins in observational study designs, including 2 published
bservational studies on the effect of reducing LDL choles-
erol with statins in which CAC progression was found to
e lower during statin treatment (72,73). These data,
owever, have been contradicted by 2 large statin clinical
rials that failed to confirm this finding, including a placebo-
ontrolled study using calcium scores (74) and a study of
ost-menopausal women treated to moderate versus inten-
ive LDL cholesterol reductions using calcium volume
cores (75). The CAC findings of the latter 2 studies are in
ontrast to the definitive reduction in cardiovascular risk
ssociated with statin therapy and suggest that either longer
eriods of monitoring of CAC would be necessary to detect
n effect of statins, that statins fundamentally alter the
elationship between calcified plaque extent and cardiovas-
ular outcomes, or that statins are affecting the noncalcified
laque and therefore no change is detectable by CAC
easurement. Management of other cardiovascular risk
actors, for example, hypertension or diabetes, has not been
xamined relative to the progression of coronary calcium.
ummary and Implications
lthough progression of CAC can be detected using fast
T methods, its determinants are largely unknown and the
elationship to clinical outcomes is still unclear. Because
rogression of CAC is not clearly modifiable through
tandard risk reducing therapies, and CAC measurement
nvolves both costs and radiation exposure, clinical moni- doring of CAC progression through serial fast CT scanning
s not recommended at this time.
ost-Effectiveness of
oronary Calcium Scoring for
isk Assessment of Cardiac Death or MI
stablishing the cost-effectiveness of testing, especially
creening tests, is quite challenging. To establish effective-
ess, CAC measurement would have to be shown to
nhance life, prolong life, or both (76). This task can be
elatively straightforward with therapies for which there are
andomized controlled clinical trials establishing efficacy in
erms of quality of life, events, or mortality. These types of
tudies do not exist for CAC measurement, as noted earlier
n this report, and in general do not exist for any cardio-
ascular test. Standards for cost-effectiveness analysis call for
valuating effects on survival, quality of life and cost using a
ifetime time horizon (76). Even for therapies which have
ajor clinical impact, such as lowering of LDL cholesterol,
nd where the clinical trial data are consistent and convinc-
ng, this is challenging to accomplish. For a single test,
hich might be expected to have a smaller impact than a
ajor therapeutic strategy, establishing cost-effectiveness
an be a difficult, if not unrealistic goal.
In the absence of clinical trial data, cost-effectiveness is
enerally approached with simulations in which decisions,
est results, and outcomes are estimated, with as much
nformation coming from the medical literature as possible.
or tests, such as CAC measurement, simulations can be
specially difficult because the test results can lead to many
ifferent possible decisions and thus many different poten-
ial outcomes. Furthermore, for evaluating any test or
herapy, it is essential to understand the nature of the
ntervention and the comparators. In the case of CAC
easurement, there are several possible ways to view how
he test would affect care and outcome, and the comparators
ay not be clear.
Despite these challenges, there have been several at-
empts to assess the cost-effectiveness of CAC scoring.
’Malley et al. (77) constructed a decision analytic model of
he addition of CAC score to the FRS. The base case
ssumed that any CAC greater than 0 would increase the
elative risk 4-fold. Multiple additional assumptions were
ade, some of which the Writing Committee members
onsidered difficult to justify. The base case offered an
ncremental cost-effectiveness ratio (ICER) of $86 752 for a
2-year-old subject. The ICER was sensitive to the gain in
ife expectancy for early intervention, the utility of being at
isk, and the added prognostic value of CAC. This study
ffers good insight into some of the problems in assessing
he cost-effectiveness of CAC, but it is the judgment of the
riting Committee that it is not sufficiently grounded in
ata to be useful for medical decision making. The authors
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January 23, 2007:378–402 ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoringpdated this analysis using the hazard ratio from the
rospective Army Coronary Calcium project, finding an
CER of $31 500 (18). This conclusion was sensitive to
ariation in the extent to which CAC actually predicts
vents (sensitivity analysis) and to assumed degree of the
fficacy of primary prevention strategies (in sensitivity anal-
sis). Furthermore, there were only 9 coronary events used
o establish the hazard ratios. The analysis is also limited by
he assumptions in the model. Shaw et al. (78) developed a
imilar decision-analytic model, finding that in individuals
ith estimated risk of coronary events below 0.6% per year,
he ICER approached $500 000, but was $42 339 if the
stimated event rate was 1% per year, and $30 742 if the
vent rate was 2% per year. This model was also highly
ependent on the underlying assumptions, as is always the
ase for any cost-effectiveness model.
ummary and Conclusion
hile several serious efforts to understand the cost-
ffectiveness of CAC measurement have been made, the
ommittee felt that models were not, and could not be,
ufficiently well grounded in data to offer results that could
e used for medical decision making or establishing policy at
his time.
pecial Considerations
AC Scores and Gender
ender differences in utility and accuracy of imaging
ests are typically related to differences in the epidemiol-
gy of coronary heart disease, with women having later
nset of clinical CHD than men. Gender differences in
ncidence and prevalence of CAD are most marked in
iddle-aged populations, the typical target age group for
HD screening. In addition, emerging data suggest that
here may be actual gender differences in the anatomy of
therosclerosis. Thus, it is important to consider gender-
pecific data when evaluating the potential uses of any
ew cardiac test.
pidemiology
omen develop coronary atherosclerosis 10 years later than
en, on average, and the occurrence of coronary calcifica-
ion tracks with this later onset of CAD. These differences
tart to diminish at about age 60 (79). These gender
ifferences in occurrence of coronary calcium support the
ssociation of CAC with coronary atherosclerosis and un-
erline the importance of age- and gender-specific reference
oints for CAC scoring (80).
isk Assessment
n general, studies of the use of coronary calcium as a
omponent of the CHD risk assessment include fewer
omen than men. Studies also vary according to the analysis
f women as a separate subgroup. Because many of the axisting studies have included women and men of similar
ge (typically between ages 50 and 60), the reported 10-year
vent rates for women have been predictably lower than in
en. Thus, many studies have been underpowered and
ncluded women at too low risk to show benefit of CAC
creening exclusively in women.
Two studies included a large enough sample of women
81) or adequate numbers of elderly patients to reach
onclusions about CAC testing in women. In a prospective,
bservational study by Raggi et al. (81), the relationship
etween CAC and all-cause mortality was analyzed by
ender in 10 377 asymptomatic individuals, of whom 40%
ere women. The mean follow-up period was 5 3.5 years.
or women, the ROC C-statistic for the prediction of
ll-cause mortality by the NCEP ATP-3 Framingham risk
alculator was 0.672 for women and increased significantly
o 0.75 with data from CAC scores added to the prediction
odels (p less than 0.0001). This analysis is limited by the
se of self-reported risk factors but showed similar relation-
hips in the predictive ability of CAC in men and women.
ortality was determined using the Social Security Na-
ional Death Index, thus these data are not specific to CHD
vents. In a study of older individuals (mean age  71
ears), the relationships between CAC score and incident
yocardial infarction were similar in men and women (22) and
emained significant in risk factor- and gender-adjusted mod-
ls (22).
ummary
here are limited data broadly specific to women on the
elationship between CHD outcomes and CAC. Existing
ata confirm an association between CAC scores and
ll-cause mortality and CHD events in elderly women.
uture studies must include enough women within an
ppropriately high clinical risk stratum (at least intermediate
ramingham risk) to be able to draw significant, clinically
elevant conclusions specific to women.
thnicity
he majority of studies which have demonstrated the
ssociation between the degree of coronary calcium, the
urden of atherosclerosis, and the risk for cardiovascular
vents associated with coronary calcium have included
rimarily Caucasian subjects. Significant racial/ethnic dif-
erences exist in the prevalence of cardiovascular risk factors
nd mortality. Blacks generally have a higher prevalence of
ypertension, diabetes and obesity, and a higher age-
djusted mortality from coronary heart disease and cardio-
ascular disease than whites (82,83). Some of these differ-
nces are attributed to socioeconomic status, access to care,
nd lifestyle factors.
Potential differences in coronary calcium prevalence
nd severity between racial/ethnic groups have begun to
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ave compared the prevalence and/or severity of CAC in
lack and white subjects. Some have found that blacks
ave less coronary calcium than whites, and others have
hown no significant differences. The largest study was
eported from MESA, which included 6814 men and
omen between the ages of 45 and 84 years without
vidence of clinical cardiovascular disease (84). The
revalence of coronary calcium was highest in the white
en (70.4%) and lowest in the black men (52.1%). The
revalence in Hispanic and Chinese men was intermedi-
te between the two (56.5% and 59.2%, respectively).
imilar results were seen in women, with white women having
he highest prevalence (44.6%), black and Hispanic women the
owest (36.5% and 34.9%, respectively), and Chinese
omen intermediate (41.9%). After adjusting for cardiovas-
ular disease risk factors the prevalence of coronary calcium
as 22% lower in blacks compared with whites, 15% lower
n Hispanics, and 8% lower in Chinese. Similar results were
een in analyses of the severity of coronary calcium in these
acial/ethnic groups (33). The MESA study recently pub-
ished detailed tables and figures describing the racial/ethnic
istribution of coronary calcium in a relatively unbiased
opulation sample (85). The exact estimated percentile for a
articular age in years is available at the MESA public Web
ite (http://www.mesa-nhlbi.org/CACReference.aspx). At
his Web site, one can enter an age (in years), gender,
ace/ethnicity (for the 4 race/ethnicity groups included in
ESA), and optionally an observed calcium score and
btain the estimated percentiles for that subset, and the
stimated percentile for the particular calcium score entered.
The Prospective Army Coronary Calcium (PACC)
roject also found a higher prevalence of coronary cal-
ium in white (19.2%) than black (10.3%) active-duty
ilitary personnel with a mean age of 42 years; the
ifference persisted after adjusting for cardiovascular
isease risk factors (86). Budoff et al. (87) described
imilar findings in white men referred for CAC testing
ompared with black men; however, in this study, black
omen had a higher prevalence of coronary calcium than
hite women. In addition, Asian men and women had a
ower prevalence of coronary calcium, and the prevalence
n Hispanics was similar to the whites. The Cardiovas-
ular Health Study (CHS) included older adults (67 to 99
ears) and found higher CAC scores in whites compared
ith blacks, especially in men (88). Interestingly, a
ubgroup analysis of subjects with a history of prior MI
lso showed lower coronary calcium scores in the black
ubgroup. Budoff et al. (89) described ethnic differences
n coronary calcium and angiographic stenosis in patients
eferred for clinically indicated coronary angiography
ho also underwent a research fast CT for CAC score.
gain, it was observed that blacks had a lower prevalence
f coronary calcium (62%) compared with whites (84%).
his correlated with a lower prevalence of significantngiographic coronary artery obstruction (49% in blacks end 71% in whites). Hispanics also had a lower preva-
ence of coronary calcium (71%) and stenosis (58%) than
hites, but there were no differences in Asians, who were
nderrepresented in this study. Sekikawa et al. (90)
ompared the prevalence of coronary calcium in 100
mericans (99% white) and 100 Japanese and found a
ignificantly lower prevalence of coronary calcium in the
apanese men (13%) than the American men (47%).
In contrast, the Dallas Heart Study is a population-
ased probability sample that includes 1289 men and
omen between the ages of 18 and 65 years, of whom
0% are black. In this study the prevalence of coronary
alcium (Agatston score greater than 10) was similar
etween black (37%) and white (41%) men, and between
lack (29%) and white (23%) women (91). In addition,
he Coronary Artery Risk Development in Young Adults
CARDIA) study also found no difference in the preva-
ence of coronary calcium in young black and white adults
etween the ages of 28 and 40 years (92), and no
ifference was found in coronary calcium scores between
lack and white postmenopausal women in the Women’s
ealth Initiative Observational Study (93).
Overall, the majority of studies demonstrate a lower
revalence and extent of coronary calcification in blacks
ompared to whites despite generally a higher prevalence
f cardiovascular risk factors in blacks. None of the
tudies has shown a higher prevalence of coronary cal-
ium in black men despite the greater age-adjusted
revalence of CHD mortality although some do show no
ifference between the 2 groups. Only a few studies have
escribed coronary calcium in Hispanic or Asian Amer-
can populations. Studies evaluating racial/ethnic dispar-
ties in CAC measurement are somewhat limited at this
ime due to lack of follow-up for cardiovascular events.
utcome studies are needed to determine whether the
ame coronary calcium score might have a different
rognosis depending on race/ethnicity. As race/ethnicity
s not always a discrete characteristic, if this is the case,
nterpretation of these scores would be difficult. It is
nclear whether racial/ethnic differences translate to
ifferences in the pathophysiology of atherosclerosis, that
s, differing degrees of calcification for the same degree of
therosclerosis, or whether some ethnic groups have a
ower burden of atherosclerotic plaque than whites. At
his time, there is limited information on how to use
oronary calcium data derived from primarily white
opulations to predict CHD in non-white populations.
n terms of racial differences in risk assessment, it should
e noted that despite ethnic differences in the use of the
RS for this purpose, there is population-based evidence
hat pre-test assessments of risk can be reliably made in
lack men and women based on the FRS (94). Thus, the
RS remains the standard approach to risk assessment
ven in ethnic minorities.
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nd End-Stage Renal Disease (ESRD)
atients with CKD and ESRD often die from cardiovas-
ular diseases. The AHA has recommended that these
atients be placed in the “highest risk” category and
herefore receive aggressive preventive therapies (95).
here is a remarkably high prevalence of coronary cal-
ium in patients with ESRD who are undergoing dialysis,
specially in young adults compared with controls
96,97). The presence and degree of coronary calcium in
hese patients may be associated with the number of years
n dialysis, the intake of supplemental calcium, and the
ean calcium-phosphorus ion product (98 –100). The
se of non-calcium phosphate binders is associated with
ess progression of coronary calcium than is calcium
arbonate (101). These findings suggest that altered
alcium metabolism is related to the pathogenesis of
rterial calcification in these patients.
Some studies suggest that patients with CKD and
SRD develop calcification in the tunica media layer of
he arterial wall, unlike the typical intimal calcification
hat is known to be associated with plaque burden (102).
he role of medial calcification as a marker of cardiovas-
ular risk is not well defined. Some studies reveal an
ssociation between coronary calcium and prevalent car-
iovascular disease in patients undergoing dialysis (98),
nd coronary calcium score is associated with risk for
otal mortality (103). An association between the degree
f coronary calcium and luminal stenosis on angiography
as been reported (104), however, other studies did not
how this association (105).
In summary, the role of CAC scoring in determining risk
n patients with CKD and/or ESRD is unclear due to a
imited number of clinical studies in these populations.
urther prospective studies are needed to determine the
tility of CAC testing in patients with CKD and ESRD for
redicting risk for CVD events.
iabetes
umerous cross-sectional studies have documented that
atients with diabetes have a higher prevalence and
xtent of coronary calcium than non-diabetic patients
106 –111). However, there is less information available
bout the utility of coronary calcium as a predictor of risk
n diabetic patients. The South Bay Heart Watch Study
ound that baseline coronary calcium predicted risk in the
on-diabetic subgroup, but not in the diabetic subgroup
n  269) (110). However, Raggi et al. (106) found that
oronary calcium predicted all-cause mortality in diabet-
cs referred for fast coronary CT scanning. Raggi et al.
106) also found that patients with diabetes have a greater
ncrease in risk for mortality associated with a given fiegree of calcium than the non-diabetic patients. A
ecent study (112) suggested that CAC scoring may be
uperior to established cardiovascular risk factors for
redicting silent myocardial ischemia and short-term
ardiovascular outcomes among stable, uncomplicated
ype 2 diabetic patients. However, while prospectively
onducted, the study included a very small number of
ard coronary events and must be confirmed by a larger
tudy.
Patients with diabetes are considered to be in the
ighest risk category according to the Adult Treatment
anel III guidelines (14). Consistent with the observation
hat diabetics have a high burden of atherosclerosis,
symptomatic diabetic patients without known CAD
ave a similar prevalence of CAC as non-diabetic pa-
ients with obstructive CAD (107). Diabetic patients
ithout any evidence of coronary calcification have a
urvival rate similar to non-diabetic patients with a zero
alcium score during 5 years of follow-up (106). These
esults suggest that coronary calcium might be useful to
urther stratify short-term risk in diabetic patients. How-
ver, until studies from non-referral populations with
onger follow-up, including fatal and non-fatal cardio-
ascular events are completed, CAC scores should not be
sed to modify treatment goals in diabetic patients.
ncidental Findings in
atients Undergoing CAC Testing
oronary calcium measurement by fast CT scanning of the
eart includes imaging of a portion of the lungs, mediasti-
um, bones and upper abdomen, in addition to the aorta.
he identification of potential pathology other than coro-
ary calcium must be considered when evaluating the
enefits and costs of cardiac CT scanning. The most
ommon incidental finding is pulmonary nodules. The
revalence of incidental findings depends on the age of the
opulation, the prevalence of smoking, and the definition of
n abnormality. Lung nodules that required clinical
ollow-up were identified in 4.9% of 1326 patients (non-
alcified lung nodules less than 1 cm, 4.0%, and lung
odules greater than 1 cm, 0.9%) in a study by Horton et al.
113) in patients with a mean age of 55 years, of whom 7%
ere active smokers and 18% former smokers. In 1000
ctive duty Army personnel with a mean age of 42 years of
hom 13% were active smokers, the prevalence of pulmo-
ary incidental findings including nodules and other pul-
onary pathology was 2.3%. Of these, approximately 50%
ere considered major, requiring subspecialty referral or
otential invasive procedures (114). In both studies, the
revalence of incidental findings in any organ system was
%; however, in the Army personnel study, 40% were
onsidered minor; whereas, in the Horton study, minor
ndings were not included.
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ACCF/AHA Expert Consensus Document on Coronary Artery Calcium Scoring January 23, 2007:378–402Occasionally a serious finding with potentially important
edical information is detected outside the coronary arteries
hen coronary calcium screening examinations are per-
ormed; therefore, it is important that the entire examina-
ion be reviewed. However, with this review, benign lesions
ill be detected as well, which can lead to additional, and
ossibly unnecessary, testing and anxiety. It is recom-
ended that current radiology guidelines be used to make
ecommendations for follow-up testing of noncardiac pa-
hology, such as was recently published to guide follow-up
or small pulmonary nodules (115).
ummary and Final Conclusions
his document has updated information on CAC measure-
ent with particular emphasis on data that have appeared
ince 2000 when the previous ACC/AHA Expert Consen-
us Document was published. In considering the data
resented here, the Expert Consensus Committee felt that
pecific clinical examples should be highlighted and clinical
ecommendations linked to these examples for use by
linicians.
The following clinical scenarios were noted to be relevant
o CAC measurement, and the Committee’s consensus on
hese questions is noted.
. What is the role of coronary calcium measurement by
coronary CT scanning in asymptomatic patients with
intermediate CHD risk (between 10% and 20% 10-year
risk of estimated coronary events)?
The Committee judged that it may be reasonable to
consider use of CAC measurement in such patients
based on available evidence that demonstrates in-
cremental risk prediction information in this se-
lected (intermediate risk) patient group. This con-
clusion is based on the possibility that such patients
might be reclassified to a higher risk status based on
high CAC score, and subsequent patient manage-
ment may be modified.
. What is the role of coronary calcium measurement by
CT scan in patients with low CHD risk (below 10%
10-year risk of estimated CHD events)?
The Committee does not recommend use of CAC
measurement in this selected patient group. This
patient group is similar to the “population screen-
ing” scenario, and the Committee does not recom-
mend screening of the general population using
CAC measurement.
. What is the role of coronary calcium measurement by
fast CT scan in asymptomatic patients with high CHD
risk (greater than 20% estimated 10-year risk of esti-
mated CHD events, or established coronary disease, or
other high-risk diagnoses)?
The Committee does not advise CAC measurement
in this selected patient stratum as they are alreadyjudged to be candidates for intensive risk reducing
therapies based on current NCEP guidelines.
. Is the evidence strong enough to reduce the treatment
intensity in patients with calcium score  0 in patients
who are considered intermediate risk before coronary
calcium score?
No evidence is available that allows the Committee to
make a consensus judgment on this question. Accord-
ingly, the Committee felt that current standard rec-
ommendations for treatment of intermediate risk pa-
tients should apply in this setting.
. Is there evidence that coronary calcium measurement is
better than other potentially competing tests in interme-
diate risk patients for modifying cardiovascular disease
risk estimate?
In general, CACmeasurement has not been compared
to alternative approaches to risk assessment in head-
to-head studies. This question cannot be adequately
answered from available data.
. Should there be additional cardiac testing when a patient
is found to have high coronary calcium score (e.g., CAC
greater than 400)?
Current clinical practice guidelines indicate that pa-
tients classified as high risk based on high risk factor
burden or existence of known high-risk disease states
(e.g., diabetes) are regarded as candidates for intensive
preventive therapies (medical treatments). There is no
clear evidence that additional non-invasive testing in
this patient population will result in more appropriate
selection of treatments.
. Is there a role of CAC testing in patients with atypical
cardiac symptoms?
Evidence indicates that patients considered to be at
low risk of coronary disease by virtue of atypical
cardiac symptoms may benefit from CAC testing to
help in ruling out the presence of obstructive coronary
disease. Other competing approaches are available,
and most of these competing modalities have not been
compared head-to-head with CAC.
. Can coronary calcium data collected to date be general-
ized to specific patient populations (women, African
American men)?
CAC data are strongest for Caucasian, non-Hispanic
men. The Committee recommends caution in extrap-
olating CAC data derived from studies in white men
to women and to ethnic minorities.
. What is the appropriate follow-up when an incidental
finding in the lungs or other non-cardiac tissues is found
on a fast coronary CT study?
Current radiology guidelines should be considered
when determining need for follow-up of incidental
findings on a fast CT study, such as that which was
recently published to guide follow-up of small pulmo-
nary nodules (115).
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